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3 Indeed, GLP-1R is a validated target for the treatment of type 2 diabetes mellitus. low molecular weight compounds that may allow oral administration. 8À15 Furthermore, new bifunctional peptides that activate GLP-1R and other molecular targets are being explored in preclinical models for enhanced antidiabetic pharmacology. 16, 17 Previous work has shown that certain β 3 -peptides can effectively mimic the side chain display of an R-helix and inhibit interactions between proteins, both in vitro 18À20 and in cultured cells. 21À23 Oligomers containing mixtures of both R-and β-amino acids have also shown success. 24 Here we describe a potential β 3 -peptide analog of GLP-1, CC-3 Act , that interacts with the GLP-1R extracellular domain (nGLP-1R) in vitro in a manner that competes with exendin-4 and induces GLP-1R-dependent cAMP signaling in cultured CHO-K1 cells expressing GLP-1R.
Our design of CC-3 Act began with the sequence of exendin-4. This sequence can be divided into two regions: a 22 residue C-terminal region that associates as an R-helix (shown in purple in Figure 1 ) with nGLP-1R (shown in gray) and functions in isolation as a receptor antagonist
) and a 9 residue N-terminal region of undefined structure that is required for receptor activation. 5, 25, 26 A large number of side chains within the C-terminal region contribute to exendin-4/GLP-1R binding and/or receptor activation. These include E 15 26 , and A/V 19 ;are conserved between exendin-4 and GLP-1 and localize on the bound R-helix at the ligandÀreceptor interface ( Figure 1C ). 27 Our design was further refined by three principles uncovered during previous efforts to develop β 3 -peptide mimics of less complex R-helical segments. 18,20À23,28,29 These efforts revealed that homo-oligomeric β 3 -peptides presenting three interacting residues on one 14-helix face often perform as designed, binding their targets with affinities <1 μM, whereas those presenting four interacting residues usually do not. These efforts also revealed that the axial orientation of the three interacting residues (N to C vs C to N) and their stereochemical relationship ( Figure 1D ) could modulate K d by more than 100-fold. The side chain that contributes most significantly to exendin-4•GLP-1R interaction is F 22 . 30 Thus, we began by identifying a collection of side chain triads containing F 22 and other components of the bound R-helix interface that could be displayed on each of two 14-helix faces and in either the N to C or C to N direction. For example, were F 22 to occupy position d of a heptad repeat, the ada side chain triad would include V 19 , F 22 , and L 26 ; were it to occupy position a, the dad triad would be A 18 , F 22 , and W 25 . Each of these three residue epitopes can be presented in two axial directions and on two 14-helix faces to generate a collection of 8 β 3 -peptides. β 3 -Peptides presenting VFW and AFL epitopes (formally adg and gda) were also prepared to generate a collection of 16 molecules ( Figure 1E ).
First we used an in vitro fluorescence polarization (FP) competition assay to compare the relative affinities of these 16 β 3 -peptides for recombinant nGLP-1R ( Figure S1 ). Each β 3 -peptide was incubated at a concentration of 10 or 50 μM with 5 nM exendin-4
Flu in the presence of 125 nM nGLP-1R, and the polarization of the mixture was monitored at equilibrium. Of the 16 β 3 -peptides evaluated, 14 had no effect on the observed polarization, even at 50 μM concentration, indicating that they had little or no effect on the fraction of exendin-4
Flu bound to the nGLP-1R under these conditions. β 3 -Peptides CC-3 and CC-11, however, both significantly reduced the observed polarization values (22% and 33% relative to exendin-4), suggesting that they compete with exendin-4
Flu for the nGLP-1R binding pocket. Incubation of 5 nM exendin-4
Flu and 125 nM nGLP-1R with between 10 nM and 500 μM CC-3 or CC-11 led to a concentration-dependent decrease in the fraction of exendin-4 Flu bound ( Figure 2A) 31 Even the modest affinity of GLP-1 for nGLP-1R is sufficient for subnanomolar potency in the context of the full-length receptor and peptide.
Three lines of evidence suggest that CC-3 and CC-11 mimic the R-helical regions of exendin-4 and GLP-1 in their interactions with nGLP-1R. First, substitution of each component of the 'AFW/VFW' epitope for alanine (CC-3.6, CC-3.9) or ornithine (CC-3.3) led to β 3 -peptides that compete poorly with exendin-4
Flu for binding to nGLP-1R ( Figure 2B) . Second, CC-3 and CC-11 differ by only two methyl groups, presenting either an AFW (CC-3) or VFW (CC-11) triad in the N-to-C orientation on the same β 3 -peptide face. Six other collection members carry one of these two side chain triads (CC-1, 2, and 4; CC-9, 10, 12), but differ from CC-3 and CC-11 in the relative orientation of the three side chains (N-to-C or C-to-N) or the stereochemical relationship of the epitope, hydrophobic, and salt bridge faces. Yet, only CC-3 and CC-11 competed effectively with exendin-4
Flu for binding to nGLP-1R ( Figure 2B) .
Finally, post hoc modeling experiments provide a structural rationale for the observed differences in affinity among β 3 -peptides possessing alternate arrangements of the same binding epitope. We used the program pepz 32 to construct models for β 3 -peptides CC-1À4 and CC-9À12 in an ideal 3 14 -helix conformation. 33 After sampling of the epitope side chains, the Cβ, Cγ, Cδ, Cε1, and Nζ1 atoms of the epitope residues were used to align each β 3 -peptide to the corresponding side chain atoms (Cβ, Cγ, Cδ, Cε1, and Nζ1) of exendin-4 in the exendin-4•nGLP-1R complex structure (PDBID 3c5t). The RMSD of these alignments varied between 1.1 and 1.4 Å (shown in Figure S2 ). While these models are too coarse to reveal detailed interactions or the precise placement of each side chain in the binding pocket, they do identify the relative orientation of side chains presented on each 3 14 helix face. In the case of CC-3 and CC-11, alignment of the AFW/VFW epitopes into the binding pocket orients the β 3 -peptide hydrophobic face, which contains three valine side chains, toward a hydrophobic groove on the GLP-1R surface, and orients the saltbridge face, which contains acidic and basic side chains, toward solvent. Reversing the C-to-N direction of the AFW/VFW epitope as in CC-1 and CC-9, or reversing the relative orientation of the salt-bridge and valine faces with respect to the epitope face as in CC-4 and CC-12, directs the salt-bridge face toward the hydrophobic groove on the nGLP-1R surface and points the hydrophobic valine side chains toward solvent. These two side chain arrangements are likely to be energetically unfavorable and destabilize the interaction of these β 3 -peptides with nGLP-1R. Interestingly, reversal of both the face ordering and the N-to-C directionality (as in CC-2 and CC-10) leads to sidechain placement similar to that of CC-3 and CC-11. In this case, the reduced 3 14 helicity of CC-2 and CC-10 may be the primary cause for their reduced binding ( Figure S3 ).
Next, CC-3 and CC-11 were converted into the potential β
